After over two years of public reporting, the State Profile Report will no longer be produced and distributed after February 2023. The final release was on February 23, 2023. We want to thank everyone who contributed to the design, production, and review of this report and we hope that it provided insight into the data trends throughout the COVID-19 pandemic. Data about COVID-19 will continue to be updated at CDC’s COVID Data Tracker. The State Profile Report (SPR) is generated by the Data Strategy and Execution Workgroup in the Joint Coordination Cell, in collaboration with the White House. It is managed by an interagency team with representatives from multiple agencies and offices (including the United States Department of Health and Human Services (HHS), the Centers for Disease Control and Prevention, the HHS Assistant Secretary for Preparedness and Response, and the Indian Health Service). The SPR provides easily interpretable information on key indicators for each state, down to the county level. It is a weekly snapshot in time that: Focuses on recent outcomes in the last seven days and changes relative to the month prior Provides additional contextual information at the county level for each state, and includes national level information Supports rapid visual interpretation of results with color thresholds
As of March 10, 2023, the state with the highest number of COVID-19 cases was California. Almost 104 million cases have been reported across the United States, with the states of California, Texas, and Florida reporting the highest numbers.
From an epidemic to a pandemic The World Health Organization declared the COVID-19 outbreak a pandemic on March 11, 2020. The term pandemic refers to multiple outbreaks of an infectious illness threatening multiple parts of the world at the same time. When the transmission is this widespread, it can no longer be traced back to the country where it originated. The number of COVID-19 cases worldwide has now reached over 669 million.
The symptoms and those who are most at risk Most people who contract the virus will suffer only mild symptoms, such as a cough, a cold, or a high temperature. However, in more severe cases, the infection can cause breathing difficulties and even pneumonia. Those at higher risk include older persons and people with pre-existing medical conditions, including diabetes, heart disease, and lung disease. People aged 85 years and older have accounted for around 27 percent of all COVID-19 deaths in the United States, although this age group makes up just two percent of the U.S. population
As of March 10, 2023, the state with the highest rate of COVID-19 cases was Rhode Island followed by Alaska. Around 103.9 million cases have been reported across the United States, with the states of California, Texas, and Florida reporting the highest numbers of infections.
From an epidemic to a pandemic The World Health Organization declared the COVID-19 outbreak as a pandemic on March 11, 2020. The term pandemic refers to multiple outbreaks of an infectious illness threatening multiple parts of the world at the same time; when the transmission is this widespread, it can no longer be traced back to the country where it originated. The number of COVID-19 cases worldwide is roughly 683 million, and it has affected almost every country in the world.
The symptoms and those who are most at risk Most people who contract the virus will suffer only mild symptoms, such as a cough, a cold, or a high temperature. However, in more severe cases, the infection can cause breathing difficulties and even pneumonia. Those at higher risk include older persons and people with pre-existing medical conditions, including diabetes, heart disease, and lung disease. Those aged 85 years and older have accounted for around 27 percent of all COVID deaths in the United States, although this age group makes up just two percent of the total population
Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
United States COVID-19: No. of Deaths: To Date: Texas data was reported at 93,780.000 Person in 10 May 2023. This records an increase from the previous number of 93,738.000 Person for 09 May 2023. United States COVID-19: No. of Deaths: To Date: Texas data is updated daily, averaging 59,608.000 Person from Jan 2020 (Median) to 10 May 2023, with 1205 observations. The data reached an all-time high of 93,780.000 Person in 10 May 2023 and a record low of 0.000 Person in 14 Mar 2020. United States COVID-19: No. of Deaths: To Date: Texas data remains active status in CEIC and is reported by Centers for Disease Control and Prevention. The data is categorized under High Frequency Database’s Disease Outbreaks – Table US.D001: Center for Disease Control and Prevention: Coronavirus Disease 2019 (COVID-2019). Data beginning Oct 19 is published weekly instead of daily. Data prior Oct 19 is based on state-level aggregate count data, while data starting Oct 19 is based on county-level aggregate count data. Discrepancies may exist due to differences between country and state COVID-19 case surveillance and reconcilaition efforts, which is why there is a decline in the data for some states.
As of March 10, 2023, there have been 1.1 million deaths related to COVID-19 in the United States. There have been 101,159 deaths in the state of California, more than any other state in the country – California is also the state with the highest number of COVID-19 cases.
The vaccine rollout in the U.S. Since the start of the pandemic, the world has eagerly awaited the arrival of a safe and effective COVID-19 vaccine. In the United States, the immunization campaign started in mid-December 2020 following the approval of a vaccine jointly developed by Pfizer and BioNTech. As of March 22, 2023, the number of COVID-19 vaccine doses administered in the U.S. had reached roughly 673 million. The states with the highest number of vaccines administered are California, Texas, and New York.
Vaccines achieved due to work of research groups Chinese authorities initially shared the genetic sequence to the novel coronavirus in January 2020, allowing research groups to start studying how it invades human cells. The surface of the virus is covered with spike proteins, which enable it to bind to human cells. Once attached, the virus can enter the cells and start to make people ill. These spikes were of particular interest to vaccine manufacturers because they hold the key to preventing viral entry.
Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
United States Excess Deaths excl COVID: Predicted: Upper Bound: Texas data was reported at 4,284.000 Number in 16 Sep 2023. This records an increase from the previous number of 4,268.000 Number for 09 Sep 2023. United States Excess Deaths excl COVID: Predicted: Upper Bound: Texas data is updated weekly, averaging 4,225.000 Number from Jan 2017 (Median) to 16 Sep 2023, with 350 observations. The data reached an all-time high of 4,692.000 Number in 04 Feb 2023 and a record low of 3,830.000 Number in 26 Aug 2017. United States Excess Deaths excl COVID: Predicted: Upper Bound: Texas data remains active status in CEIC and is reported by Centers for Disease Control and Prevention. The data is categorized under Global Database’s United States – Table US.G012: Number of Excess Deaths: by States: All Causes excluding COVID-19: Predicted (Discontinued).
Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
United States Excess Death excl COVID: Predicted: Single Excess Est: Texas data was reported at 77.000 Number in 16 Sep 2023. This records an increase from the previous number of 0.000 Number for 09 Sep 2023. United States Excess Death excl COVID: Predicted: Single Excess Est: Texas data is updated weekly, averaging 39.000 Number from Jan 2017 (Median) to 16 Sep 2023, with 350 observations. The data reached an all-time high of 900.000 Number in 13 Jan 2018 and a record low of 0.000 Number in 09 Sep 2023. United States Excess Death excl COVID: Predicted: Single Excess Est: Texas data remains active status in CEIC and is reported by Centers for Disease Control and Prevention. The data is categorized under Global Database’s United States – Table US.G012: Number of Excess Deaths: by States: All Causes excluding COVID-19: Predicted (Discontinued).
Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
BackgroundUnderstanding the distinct immunologic responses to SARS-CoV-2 infection among pediatric populations is pivotal in navigating the COVID-19 pandemic and informing future public health strategies. This study aimed to identify factors associated with heightened antibody responses in children and adolescents to identify potential unique immune dynamics in this population.MethodsData collected between July and December 2023 from the Texas Coronavirus Antibody REsponse Survey (Texas CARES), a statewide prospective population-based antibody survey among 1-to-19-year-old participants, were analyzed. Each participant had the following data available for analysis: (1) Roche Elecsys® Anti-SARS-CoV-2 Immunoassay for Nucleocapsid protein antibodies (Roche N-test), (2) qualitative and semi-quantitative detection of antibodies to the SARS CoV-2 spike protein receptor binding domain (Roche S-test), and (3) self-reported antigen/PCR COVID-19 test results, vaccination, and health status. Statistical analysis identified associations between participant characteristics and spike antibody quartile group.ResultsThe analytical sample consisted of 411 participants (mean age 12.2 years, 50.6% female). Spike antibody values ranged from a low of 6.3 U/ml in the lowest quartile to a maximum of 203,132.0 U/ml in the highest quartile in the aggregate sample. Older age at test date (OR = 1.22, 95% CI: 1.12, 1.35, p
Data for CDC’s COVID Data Tracker site on Rates of COVID-19 Cases and Deaths by Updated (Bivalent) Booster Status. Click 'More' for important dataset description and footnotes
Webpage: https://covid.cdc.gov/covid-data-tracker/#rates-by-vaccine-status
Dataset and data visualization details:
These data were posted and archived on May 30, 2023 and reflect cases among persons with a positive specimen collection date through April 22, 2023, and deaths among persons with a positive specimen collection date through April 1, 2023. These data will no longer be updated after May 2023.
Vaccination status: A person vaccinated with at least a primary series had SARS-CoV-2 RNA or antigen detected on a respiratory specimen collected ≥14 days after verifiably completing the primary series of an FDA-authorized or approved COVID-19 vaccine. An unvaccinated person had SARS-CoV-2 RNA or antigen detected on a respiratory specimen and has not been verified to have received COVID-19 vaccine. Excluded were partially vaccinated people who received at least one FDA-authorized vaccine dose but did not complete a primary series ≥14 days before collection of a specimen where SARS-CoV-2 RNA or antigen was detected. A person vaccinated with a primary series and a monovalent booster dose had SARS-CoV-2 RNA or antigen detected on a respiratory specimen collected ≥14 days after verifiably receiving a primary series of an FDA-authorized or approved vaccine and at least one additional dose of any monovalent FDA-authorized or approved COVID-19 vaccine on or after August 13, 2021. (Note: this definition does not distinguish between vaccine recipients who are immunocompromised and are receiving an additional dose versus those who are not immunocompromised and receiving a booster dose.) A person vaccinated with a primary series and an updated (bivalent) booster dose had SARS-CoV-2 RNA or antigen detected in a respiratory specimen collected ≥14 days after verifiably receiving a primary series of an FDA-authorized or approved vaccine and an additional dose of any bivalent FDA-authorized or approved vaccine COVID-19 vaccine on or after September 1, 2022. (Note: Doses with bivalent doses reported as first or second doses are classified as vaccinated with a bivalent booster dose.) People with primary series or a monovalent booster dose were combined in the “vaccinated without an updated booster” category.
Deaths: A COVID-19–associated death occurred in a person with a documented COVID-19 diagnosis who died; health department staff reviewed to make a determination using vital records, public health investigation, or other data sources. Per the interim guidance of the Council of State and Territorial Epidemiologists (CSTE), this should include persons whose death certificate lists COVID-19 disease or SARS-CoV-2 as the underlying cause of death or as a significant condition contributing to death. Rates of COVID-19 deaths by vaccination status are primarily reported based on when the patient was tested for COVID-19. In select jurisdictions, deaths are included that are not laboratory confirmed and are reported based on alternative dates (i.e., onset date for most; or date of death or report date, where onset date is unavailable). Deaths usually occur up to 30 days after COVID-19 diagnosis.
Participating jurisdictions: Currently, these 24 health departments that regularly link their case surveillance to immunization information system data are included in these incidence rate estimates: Alabama, Arizona, Colorado, District of Columbia, Georgia, Idaho, Indiana, Kansas, Kentucky, Louisiana, Massachusetts, Michigan, Minnesota, Nebraska, New Jersey, New Mexico, New York, New York City (NY), North Carolina, Rhode Island, Tennessee, Texas, Utah, and West Virginia; 23 jurisdictions also report deaths among vaccinated and unvaccinated people. These jurisdictions represent 48% of the total U.S. population and all ten of the Health and Human Services Regions. This list will be updated as more jurisdictions participate.
Incidence rate estimates: Weekly age-specific incidence rates by vaccination status were calculated as the number of cases or deaths divided by the number of people vaccinated with a primary series, overall or with/without a booster dose (cumulative) or unvaccinated (obtained by subtracting the cumulative number of people vaccinated with at least a primary series and partially vaccinated people from the 2019 U.S. intercensal population estimates) and multiplied by 100,000. Overall incidence rates were age-standardized using the 2000 U.S. Census standard population. To estimate population counts for ages 6-12 months, half of the single-year population counts for ages <12 months were used. All rates are plotted by positive specimen collection date to reflect when incident infections occurred.
Continuity correction: A continuity correction has been applied to the denominators by capping the percent population coverage at 95%. To do this, we assumed that at least 5% of each age group would always be unvaccinated in each jurisdiction. Adding this correction ensures that there is always a reasonable denominator for the unvaccinated population that would prevent incidence and death rates from growing unrealistically large due to potential overestimates of vaccination coverage.
Incidence rate ratios (IRRs): IRRs for the past one month were calculated by dividing the average weekly incidence rates among unvaccinated people by that among people vaccinated without an updated (bivalent) booster dose) or vaccinated with an updated (bivalent) booster dose.
Archive: An archive of historic data, including April 3, 2021-September 24, 2022 and posted on October 21, 2022 is available on data.cdc.gov. The analysis by vaccination status (unvaccinated and at least a primary series) for 31 jurisdictions is posted here: https://data.cdc.gov/Public-Health-Surveillance/Rates-of-COVID-19-Cases-or-Deaths-by-Age-Group-and/3rge-nu2a. The analysis for one booster dose (unvaccinated, primary series only, and at least one booster dose) in 31 jurisdictions is posted here: https://data.cdc.gov/Public-Health-Surveillance/Rates-of-COVID-19-Cases-or-Deaths-by-Age-Group-and/d6p8-wqjm. The analysis for two booster doses (unvaccinated, primary series only, one booster dose, and at least two booster doses) in 28 jurisdictions is posted here: https://data.cdc.gov/Public-Health-Surveillance/Rates-of-COVID-19-Cases-or-Deaths-by-Age-Group-and/ukww-au2k.
References
Scobie HM, Johnson AG, Suthar AB, et al. Monitoring Incidence of COVID-19 Cases, Hospitalizations, and Deaths, by Vaccination Status — 13 U.S. Jurisdictions, April 4–July 17, 2021. MMWR Morb Mortal Wkly Rep 2021;70:1284–1290.
Johnson AG, Amin AB, Ali AR, et al. COVID-19 Incidence and Death Rates Among Unvaccinated and Fully Vaccinated Adults with and Without Booster Doses During Periods of Delta and Omicron Variant Emergence — 25 U.S. Jurisdictions, April 4–December 25, 2021. MMWR Morb Mortal Wkly Rep 2022;71:132–138
Johnson AG, Linde L, Ali AR, et al. COVID-19 Incidence and Mortality Among Unvaccinated and Vaccinated Persons Aged ≥12 Years by Receipt of Bivalent Booster Doses and Time Since Vaccination — 24 U.S. Jurisdictions, October 3, 2021–December 24, 2022. MMWR Morb Mortal Wkly Rep 2023;72:145–152
As of March 10, 2023, the death rate from COVID-19 in the state of New York was 397 per 100,000 people. New York is one of the states with the highest number of COVID-19 cases.
In 2023, and since the outbreak of COVID-19 in the United States, Texas was the state with the most lawsuits filed against employers to do with negligence or wrongful death cases. California, the most populous state, had almost *** fewer of the same negligence related lawsuits.
Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
United States Excess Death excl COVID: Predicted: Total Excess Est: Texas data was reported at 33,158.000 Number in 16 Sep 2023. This stayed constant from the previous number of 33,158.000 Number for 09 Sep 2023. United States Excess Death excl COVID: Predicted: Total Excess Est: Texas data is updated weekly, averaging 33,158.000 Number from Jan 2017 (Median) to 16 Sep 2023, with 350 observations. The data reached an all-time high of 33,158.000 Number in 16 Sep 2023 and a record low of 33,158.000 Number in 16 Sep 2023. United States Excess Death excl COVID: Predicted: Total Excess Est: Texas data remains active status in CEIC and is reported by Centers for Disease Control and Prevention. The data is categorized under Global Database’s United States – Table US.G012: Number of Excess Deaths: by States: All Causes excluding COVID-19: Predicted (Discontinued).
Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
This dataset supports the analysis presented in the manuscript The True Cost of Heat: Evaluating Heat-Related Mortality Estimation Methods in Texas.
totals-by-day-texas.csv
Daily all-cause mortality counts for Texas counties from 2013 to 2022, including COVID-19 and mass shooting deaths, which are subtracted in the analysis. Data obtained via public records request by The Texas Tribune from the Texas Department of State Health Services.
griddedTXmeanTemp.nc
ERA5 reanalysis daily mean surface temperature data (in Celsius) for Texas counties from 1950 to 2023. Provided in NetCDF format.
Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
United States Excess Deaths excl COVID: Predicted: No. of Deaths: Texas data was reported at 4,173.000 Number in 16 Sep 2023. This records an increase from the previous number of 3,896.000 Number for 09 Sep 2023. United States Excess Deaths excl COVID: Predicted: No. of Deaths: Texas data is updated weekly, averaging 4,145.000 Number from Jan 2017 (Median) to 16 Sep 2023, with 350 observations. The data reached an all-time high of 5,100.000 Number in 13 Jan 2018 and a record low of 3,397.000 Number in 15 Jul 2017. United States Excess Deaths excl COVID: Predicted: No. of Deaths: Texas data remains active status in CEIC and is reported by Centers for Disease Control and Prevention. The data is categorized under Global Database’s United States – Table US.G012: Number of Excess Deaths: by States: All Causes excluding COVID-19: Predicted (Discontinued).
State-reported data on Medicaid and CHIP eligibility renewals that reflect the outcomes of previously pending renewals three months after the renewal was due and also any corrections to the original renewal data submitted to CMS. See here for original renewal data.
CMS renewal data specifications require states to update and submit to CMS their monthly renewal outcome metrics - metric 5 data and its submetrics (monthly metrics 5a, 5a(1), 5a(2), 5b, 5c, and 5d) - after the original monthly report submission. The “updated” renewal data reflect the outcomes of renewals previously reported as pending (monthly metric 5d of the original monthly report) as of three months after the renewal was due. For more information about this data set and considerations for users when reviewing, please see the Medicaid and CHIP Unwinding: Data Sources and Metrics Definitions Overview found here.
Sources:
(1) March 2023 state Medicaid and CHIP Renewal and Termination Data for the Unwinding Data Report pulled on March 05, 2024, representing the updated disposition of renewals due in March 2023 as of June 2023. April 2023 state Medicaid and CHIP Renewal and Termination Data for the Unwinding Data Report pulled on March 05, 2024, representing the updated disposition of renewals due in April 2023 as of July 2023. May 2023 state Medicaid and CHIP Renewal and Termination Data for the Unwinding Data Report pulled on March 05, 2024, representing the updated disposition of renewals due in May 2023 as of August 2023. June 2023 state Medicaid and CHIP Renewal and Termination Data for the Unwinding Data Report pulled on March 05, 2024, representing the updated disposition of renewals due in June 2023 as of September 2023. July 2023 state Medicaid and CHIP Renewal and Termination Data for the Unwinding Data Report pulled on March 05, 2024, representing the updated disposition of renewals due in July 2023 as of October 2023. August 2023 state Medicaid and CHIP Renewal and Termination Data for the Unwinding Data Report pulled on March 05, 2024, representing the updated disposition of renewals due in August 2023 as of November 2023. September 2023 state Medicaid and CHIP Renewal and Termination Data for the Unwinding Data Report pulled on April 02, 2024, representing the updated disposition of renewals due in September 2023 as of December 2023. October 2023 state Medicaid and CHIP Renewal and Termination Data for the Unwinding Data Report pulled on April 02, 2024, representing the updated disposition of renewals due in October 2023 as of January 2024. November 2023 state Medicaid and CHIP Renewal and Termination Data for the Unwinding Data Report pulled on May 07, 2024, representing the updated disposition of renewals due in November 2023 as of February 2024. December 2023 state Medicaid and CHIP Renewal and Termination Data for the Unwinding Data Report pulled on June 11, 2024, representing the updated disposition of renewals due in December 2023 as of March 2024. New Hampshire’s December 2023 state Medicaid and CHIP Renewal and Termination Data for the Unwinding Data Report pulled on April 09, 2024, representing the updated disposition of renewals due in December 2023 as of March 2024. New York’s December 2023 state Medicaid and CHIP Renewal and Termination Data for the Unwinding Data Report pulled on April 22, 2024, representing the updated disposition of renewals due in December 2023 as of March 2024. January 2024 state Medicaid and CHIP Renewal and Termination Data for the Unwinding Data Report pulled on July 02, 2024, representing the updated disposition of renewals due in January 2024 as of April 2024. February 2024 state Medicaid and CHIP Renewal and Termination Data for the Unwinding Data Report pulled on August 06, 2024, representing the updated disposition of renewals due in February 2024 as of May 2024. March 2024 state Medicaid and CHIP Renewal and Termination Data for the Unwinding Data Report pulled on September 09, 2024, representing the updated disposition of renewals due in March 2024 as of June 2024.
Notes: States report updated renewal outcomes for a cohort as of three months after the month renewals are scheduled for completion, unless otherwise noted. In the March 2023 – October 2023 reporting periods, Oklahoma included outcomes for some individuals who returned their renewal form during the reconsideration period. See the Data Sources and Definitions Overview document for a full description of the metric definitions and how they relate to each other.
April 2023: Ohio reported updated renewal outcomes for the cohort as of 10/31/2023. Arkansas and Pennsylvania reported the eligibility status of the cohort, and data may include outcomes of eligibility actions that occurred after the renewal.
May 2023: The following states reported updated renewal outcomes for the cohort as of a different date: Ohio (outcomes as of 10/31/2023), Rhode Island (outcomes as of 11/1/2023), South Carolina (outcomes as of 12/20/2023), and Texas (outcomes as of 9/8/2023). Pennsylvania, Rhode Island, and South Carolina updated the eligibility status of the cohort, and data may include eligibility actions that occurred after the renewal.
June 2023: The following states reported updated renewal outcomes for the cohort as of a different date: Kansas (outcomes as of 8/31/23), Minnesota (outcomes as of 12/2023), Ohio (outcomes as of 10/31/2023), North Carolina (outcomes as of 12/1/2023), Rhode Island (outcomes as of 11/1/2023), and South Carolina (outcomes as of 12/20/2023). Pennsylvania, Rhode Island, and South Carolina updated the eligibility status of the cohort, and data may include eligibility actions that occurred after the renewal.
July 2023: The following states reported updated renewal outcomes for the cohort as of a different date: Minnesota (outcomes as of 12/2023), North Carolina (outcomes as of 12/1/2023), Rhode Island (outcomes as of 11/1/2023), and Texas (outcomes as of 11/9/2023). California, Pennsylvania, and Rhode Island updated the eligibility status of the cohort, and data may include eligibility actions that occurred after the renewal.
August 2023: The following states reported updated renewal outcomes for the cohort as of a different date: Minnesota (outcomes as of 12/2023), North Carolina (outcomes as of 12/1/2023), Rhode Island (outcomes as of 12/4/2023), and South Carolina (outcomes as of 12/20/2023). California, Pennsylvania, Rhode Island, and South Carolina updated the eligibility status of the cohort, and data may include eligibility actions that occurred after the renewal.
September 2023: The following states reported updated renewal outcomes for the cohort as of a different date: Minnesota (outcomes as of 1/8/2024), North Carolina (1/2/2024), Rhode Island (1/1/2024), and South Carolina (outcomes as of 1/8/2024). California, Pennsylvania, Rhode Island, and South Carolina updated the eligibility status of the cohort, and data may include eligibility actions that occurred after the renewal. Vermont excluded renewal outcomes for some individuals who requested voluntary terminations or who were deceased.
October 2023: The following states reported updated renewal outcomes for the cohort as of a different date: Minnesota (outcomes as of 2/12/2024), North Carolina (outcomes as of 2/1/2024), Rhode Island (outcomes as of 2/15/2024), and South Carolina (outcomes as 2/1/2024). California, Pennsylvania, and South Carolina updated the eligibility status of the cohort, and data may include eligibility actions that occurred after the renewal. Rhode Island’s updated data includes some individuals reported as pending whose renewal was completed.
November 2023: The following states reported updated renewal outcomes for the cohort as of a different date: Minnesota (outcomes as of 3/4/2024), New York (outcomes as of 3/31/2024), North Carolina (outcomes as of 3/1/2024), Rhode Island (outcomes as of 4/1/2024), and South Carolina (outcomes as of 3/1/2024). Pennsylvania and South Carolina updated the eligibility status of the cohort, and data may include eligibility actions that occurred after the renewal. Rhode Island’s updated data includes some individuals reported as pending whose renewal was completed. California included outcomes for some individuals whose eligibility was redetermined based on a change in circumstances after the renewal was processed.
December 2023: The following states reported updated renewal outcomes for the cohort as of a different date: North Carolina (outcomes as of 4/1/2024) and Minnesota (outcomes as of 4/2/2024). Pennsylvania updated the eligibility status of the cohort, and data may include eligibility actions that occurred after the renewal. California included outcomes for some individuals whose eligibility was redetermined based on a change in circumstances after the renewal was processed.
January 2024: The following states reported updated renewal outcomes for the cohort as of a different date: North Carolina (outcomes as of 5/1/2024) and Minnesota (outcomes as of 5/6/2024). Pennsylvania updated the eligibility status of the cohort, and data may include eligibility actions that occurred after the renewal.
February 2024: The following states reported updated renewal outcomes for the cohort as of a different date: North Carolina (outcomes as of 6/3/2024) and Minnesota (outcomes as of 6/5/2024). Pennsylvania and Wyoming
Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
(停止更新)新冠疫情:死亡人数:迄今为止:德州在05-10-2023达93,780.000人,相较于05-09-2023的93,738.000人有所增长。(停止更新)新冠疫情:死亡人数:迄今为止:德州数据按日更新,01-22-2020至05-10-2023期间平均值为59,608.000人,共1205份观测结果。该数据的历史最高值出现于05-10-2023,达93,780.000人,而历史最低值则出现于03-14-2020,为0.000人。CEIC提供的(停止更新)新冠疫情:死亡人数:迄今为止:德州数据处于定期更新的状态,数据来源于Centers for Disease Control and Prevention,数据归类于高频数据库的流行病爆发 – Table US.D001: Center for Disease Control and Prevention: Coronavirus Disease 2019 (COVID-2019)。
Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
(停止更新)超额死亡(ED)不包括因新冠而死亡者:预期:Avg No of Deaths:德州在09-16-2023达4,096.000数量,相较于09-09-2023的4,082.000数量有所增长。(停止更新)超额死亡(ED)不包括因新冠而死亡者:预期:Avg No of Deaths:德州数据按周更新,01-07-2017至09-16-2023期间平均值为4,031.500数量,共350份观测结果。该数据的历史最高值出现于01-28-2023,达4,513.000数量,而历史最低值则出现于08-26-2017,为3,657.000数量。CEIC提供的(停止更新)超额死亡(ED)不包括因新冠而死亡者:预期:Avg No of Deaths:德州数据处于定期更新的状态,数据来源于Centers for Disease Control and Prevention,数据归类于全球数据库的美国 – Table US.G012: Number of Excess Deaths: by States: All Causes excluding COVID-19: Predicted (Discontinued)。
Not seeing a result you expected?
Learn how you can add new datasets to our index.
After over two years of public reporting, the State Profile Report will no longer be produced and distributed after February 2023. The final release was on February 23, 2023. We want to thank everyone who contributed to the design, production, and review of this report and we hope that it provided insight into the data trends throughout the COVID-19 pandemic. Data about COVID-19 will continue to be updated at CDC’s COVID Data Tracker. The State Profile Report (SPR) is generated by the Data Strategy and Execution Workgroup in the Joint Coordination Cell, in collaboration with the White House. It is managed by an interagency team with representatives from multiple agencies and offices (including the United States Department of Health and Human Services (HHS), the Centers for Disease Control and Prevention, the HHS Assistant Secretary for Preparedness and Response, and the Indian Health Service). The SPR provides easily interpretable information on key indicators for each state, down to the county level. It is a weekly snapshot in time that: Focuses on recent outcomes in the last seven days and changes relative to the month prior Provides additional contextual information at the county level for each state, and includes national level information Supports rapid visual interpretation of results with color thresholds